Secondary outcomes include AF burden, PACs count, echocardiographic parameters, cardiac biomarkers (cTnI and NT-proBNP), quality of life (FACT-G), functional status (ECOG), clinical symptom scores, and anxiety scores (SAS) at 3 and 6 months, as well as safety assessments.<h4>Discussion</h4>This study is designed to provide high-level clinical evidence for the use of WXKL in the treatment of anthracycline-induced atrial arrhythmias. The gene discussed is NPPB; the disease is atrial fibrillation.